Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KETALAR vs DIPRIVAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Noncompetitive NMDA receptor antagonist; inhibits glutamate activity, modulates opioid receptors, and interacts with other neurotransmitter systems.
Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.
Induction and maintenance of general anesthesia,Procedural sedation and analgesia,Treatment of refractory status epilepticus (off-label),Major depressive disorder with suicidal ideation (off-label)
Induction and maintenance of general anesthesia,Sedation for intubated, mechanically ventilated patients in intensive care units,Monitored anesthesia care (MAC) sedation,Treatment of refractory status epilepticus (off-label),Procedural sedation (off-label)
1-4.5 mg/kg IV or 6.5-13 mg/kg IM for induction of anesthesia; 0.1-0.5 mg/kg/min IV infusion for maintenance.
Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.
Terminal elimination half-life: 2.5-3 hours (ketamine); norketamine: 12 hours. Clinical context: Short half-life facilitates rapid recovery, but context-sensitive half-life increases with infusion duration.
Terminal elimination half-life: 4-7 hours (with context of context-sensitive half-life increasing after prolonged infusion).
Primarily hepatic via N-demethylation by CYP3A4 and CYP2B6 to norketamine, then further metabolized via hydroxylation and conjugation.
Primarily hepatic conjugation to inactive metabolites (propofol glucuronide), with minor metabolism via CYP2B6 and CYP2C9 to 4-hydroxypropofol.
Renal: 90% as metabolites (norketamine, dehydronorketamine); unchanged: 2-4%. Fecal: <3%.
Renal (approximately 88% as metabolites, <1% unchanged); fecal (approximately 2%); other (10% as metabolites via other routes).
12-50% primarily to albumin and alpha-1-acid glycoprotein.
95-99% bound, primarily to albumin.
1-2 L/kg (large, indicating extensive tissue distribution). Highly lipophilic, crosses blood-brain barrier rapidly.
2-10 L/kg (large Vd indicating extensive tissue distribution).
Oral: 16-24% (extensive first-pass metabolism); Intranasal: 45-50%; IM: 93%; Subcutaneous: 100%.
Intravenous: 100%; not available orally due to extensive first-pass metabolism.
No dose adjustment required for GFR >10 m L/min; for GFR <10 m L/min, consider dose reduction by 50% due to accumulation of active metabolite norketamine.
No adjustment required; propofol is not significantly renally eliminated.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use or use with extreme caution, reduce dose by 75%.
No specific Child-Pugh based guidelines; use lower doses due to impaired clearance, especially in cirrhosis.
Induction: 1-2 mg/kg IV or 4-6 mg/kg IM; maintenance: 0.5-1 mg/kg IV boluses or 10-50 mcg/kg/min IV infusion. Titrate to effect.
Induction: 2.5-3.5 mg/kg IV bolus; maintenance: 125-300 mcg/kg/min IV infusion. Not approved for ICU sedation in <16 years.
Reduce initial dose by 50% (e.g., 0.5-2 mg/kg IV) and titrate slowly due to increased sensitivity and risk of delirium; consider lower infusion rates (0.1-0.3 mg/kg/min).
Reduce induction dose to 1-1.5 mg/kg IV bolus and maintenance infusion to 20-50 mcg/kg/min IV due to increased sensitivity and decreased clearance.
Hemodynamic instability (hypertension, tachycardia) and increased intracranial pressure; risk of emergent reactions (hallucinations, delirium); potential for abuse and dependence.
Propofol should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the surgical/diagnostic procedure. Patients should be continuously monitored for early signs of hypotension, bradycardia, apnea, airway obstruction, and oxygen desaturation. For sedation of intubated, mechanically ventilated patients in the ICU, propofol should be used with caution in patients with increased intracranial pressure or impaired cerebral circulation.
Monitor blood pressure and cardiac function; use with caution in patients with hypertension, heart failure, or increased intracranial pressure; emergence reactions may occur; laryngospasm risk; respiratory depression.
Risk of hypotension and bradycardia, especially in elderly or hypovolemic patients,Respiratory depression and apnea requiring airway management,Propofol infusion syndrome (PRIS): metabolic acidosis, rhabdomyolysis, renal failure, cardiac failure, especially with prolonged high-dose infusions,Hypertriglyceridemia; monitor lipids with prolonged use,Risk of pancreatitis,Use with caution in patients with epilepsy; may increase seizure risk during withdrawal,May cause green discoloration of urine, hair, or nails
Hypersensitivity to ketamine; conditions where elevated blood pressure or intracranial pressure would be dangerous (e.g., severe hypertension, cerebral hemorrhage); severe coronary artery disease; history of psychotic disorders.
Hypersensitivity to propofol or any component of the formulation,Hypersensitivity to eggs, egg products, soybeans, or soy products (due to lipid vehicle),Patients with severe lipid metabolism disorders (e.g., hyperlipidemia),Not recommended for general anesthesia in patients with increased intracranial pressure or impaired cerebral circulation unless benefits outweigh risks
No specific food interactions; avoid alcohol for 24 hours due to additive CNS depression.
No specific food interactions; however, propofol emulsion contains soybean oil and egg lecithin, so avoid in patients with egg or soy allergies. The emulsion can be contaminated if bottle is reused; discard after single use. No dietary restrictions required for administration.
First trimester: Limited human data; animal studies show no teratogenicity. Second/third trimester: Use only if clearly needed; may cause neonatal respiratory depression, hypotonia, and altered neurobehavior if used near delivery.
Propofol (DIPRIVAN) is Pregnancy Category B. Animal studies at clinical doses did not show teratogenicity. Use in first trimester only if clearly needed. During second and third trimesters, propofol crosses the placenta and may cause neonatal respiratory depression and neurobehavioral depression. Risk of fetal acidosis and bradycardia. No major teratogenic effects reported in human studies, but limited data.
Excreted into breast milk in low amounts; M/P ratio unknown. Use caution, especially with repeated doses or in neonates with hepatic impairment.
Propofol is excreted into breast milk in low concentrations. M/P ratio not established. Due to low oral bioavailability, risk to infant is minimal. However, caution is advised due to potential CNS depression in neonates. The manufacturer recommends discontinuing breastfeeding for 24 hours after administration.
No specific dose adjustment required for pregnancy; consider reduced dose due to increased volume of distribution and clearance in late pregnancy. Use lowest effective dose.
Pharmacokinetic changes in pregnancy include increased volume of distribution and clearance, particularly in the third trimester. No specific dose adjustment guidelines; clinical response and patient condition determine dosing. Reduced doses may be required due to increased sensitivity to propofol in pregnancy.
Ketamine (Ketalar) produces dissociative anesthesia with potent analgesia. Onset of action is rapid (30 seconds IV, 5 minutes IM). Emergence reactions (hallucinations, delirium) can be mitigated with benzodiazepines. Contraindicated in patients with hypertension, aneurysms, or increased intracranial pressure due to sympathomimetic effects. Use with caution in patients with psychosis or thyroid disorders.
DIPRIVAN (propofol) causes pain on injection, especially in small veins; pretreatment with lidocaine or use of a larger vein can mitigate. It is formulated as a lipid emulsion containing soybean oil and egg lecithin, thus contraindicated in patients with egg or soybean allergies. Propofol can cause profound hypotension and respiratory depression; ensure airway equipment and vasopressors are immediately available. The infusion syndrome (PRIS) is rare but lethal, characterized by metabolic acidosis, rhabdomyolysis, and cardiac failure; avoid prolonged high-dose infusions (>5 mg/kg/hr for >48 hours).
You may experience vivid dreams or hallucinations as the medication wears off; this is common and can be reduced with other medications.,Do not drive, operate machinery, or make important decisions for at least 24 hours after receiving ketamine.,Avoid alcohol and other sedatives for 24 hours after administration.,Inform your healthcare provider if you have high blood pressure, heart disease, or a history of psychosis.
You will be monitored continuously during and after administration due to risk of low blood pressure and slowed breathing.,You may feel a burning or stinging sensation at the injection site; inform your healthcare provider if it persists.,Do not drive or operate machinery for at least 24 hours after receiving propofol due to residual sedation.,Inform your medical team if you have allergies to eggs, soy, or sesame seeds.,Propofol is not intended for home use; it is only administered in a supervised medical setting.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KETALAR vs DIPRIVAN, answered by our medical review team.
KETALAR is a General Anesthetic that works by Noncompetitive NMDA receptor antagonist; inhibits glutamate activity, modulates opioid receptors, and interacts with other neurotransmitter systems.. DIPRIVAN is a General Anesthetic that works by Propofol potentiates GABA-A receptor activity, leading to rapid sedation and hypnosis by enhancing chloride conductance and neuronal hyperpolarization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KETALAR and DIPRIVAN depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KETALAR is: 1-4.5 mg/kg IV or 6.5-13 mg/kg IM for induction of anesthesia; 0.1-0.5 mg/kg/min IV infusion for maintenance.. The standard adult dose of DIPRIVAN is: Induction: 2-2.5 mg/kg IV bolus; maintenance: 25-75 mcg/kg/min IV infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KETALAR and DIPRIVAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KETALAR is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity. Second/third trimester: Use only if clearly needed; may cause neonatal respiratory depression, hypotonia. DIPRIVAN is classified as Category C. Propofol (DIPRIVAN) is Pregnancy Category B. Animal studies at clinical doses did not show teratogenicity. Use in first trimester only if clearly needed. During second and third tr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.